PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
IHE vs. GERM
Performance
Return for Risk
Drawdowns
Volatility
Dividends

IHE vs. GERM

Last updated Jun 26, 2026

IHE (iShares U.S. Pharmaceuticals ETF) and GERM (Amplify Treatments, Testing and Advancements ETF) are both Health & Biotech Equities funds - IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index while GERM tracks the Prime Treatments, Testing and Advancements Index. Both are passively managed. Over the past year, IHE returned 48.10% vs 0.00% for GERM. IHE charges 0.42%/yr vs 0.68%/yr for GERM.

Performance

IHE vs. GERM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares U.S. Pharmaceuticals ETF (IHE) and Amplify Treatments, Testing and Advancements ETF (GERM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

IHE

1D
0.90%
1M
5.53%
YTD
13.81%
6M
11.99%
1Y
48.10%
3Y*
19.70%
5Y*
10.84%
10Y*
9.50%

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
—
5Y*
—
10Y*
—
*Multi-year figures are annualized to reflect compound growth (CAGR)

IHE vs. GERM - Yearly Performance Comparison

2026 (YTD)20252024
IHE
iShares U.S. Pharmaceuticals ETF		13.81%31.69%-7.21%
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%

IHE vs. GERM - Sectors Allocation Comparison

Sectors
IHE
GERM

Healthcare

100.0%
99.3%

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Financial Services

-

0.4%

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

IHE
100.0%
GERM
99.3%

Basic Materials

IHE

-

GERM

-

Communication Services

IHE

-

GERM

-

Consumer Cyclical

IHE

-

GERM

-

Consumer Defensive

IHE

-

GERM

-

Energy

IHE

-

GERM

-

Financial Services

IHE

-

GERM
0.4%

Industrials

IHE

-

GERM

-

Real Estate

IHE

-

GERM

-

Technology

IHE

-

GERM

-

Utilities

IHE

-

GERM

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

iShares U.S. Pharmaceuticals ETF

Amplify Treatments, Testing and Advancements ETF

Often compared with IHE:
IHE vs. PPHIHE vs. XPHIHE vs. XLVIHE vs. VYMIHE vs. PJPIHE vs. IAKIHE vs. BBP
Often compared with GERM:
GERM vs. SBIOGERM vs. EQRRGERM vs. GDOCGERM vs. XBIGERM vs. ARKGGERM vs. XLVGERM vs. MDEV

Return for Risk

IHE vs. GERM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
IHE
IHE Risk / Return Rank: 9191
Overall Rank
IHE Sharpe Ratio Rank: 9292
Sharpe Ratio Rank
IHE Sortino Ratio Rank: 9393
Sortino Ratio Rank
IHE Omega Ratio Rank: 8888
Omega Ratio Rank
IHE Calmar Ratio Rank: 9393
Calmar Ratio Rank
IHE Martin Ratio Rank: 9090
Martin Ratio Rank
GERM

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IHE vs. GERM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares U.S. Pharmaceuticals ETF (IHE) and Amplify Treatments, Testing and Advancements ETF (GERM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

IHEGERMDifference
Sharpe ratioReturn per unit of total volatility
2.81

—

—

Sortino ratioReturn per unit of downside risk
4.03

—

—

Omega ratioGain probability vs. loss probability

1.47

—

—

Calmar ratioReturn relative to maximum drawdown

5.70

—

—

Martin ratioReturn relative to average drawdown

17.54

—

—

IHE vs. GERM - Sharpe Ratio Comparison

Loading charts...

Drawdowns

IHE vs. GERM - Drawdown Comparison

The maximum IHE drawdown since its inception was -38.20%, which is greater than GERM's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IHE and GERM.

Loading charts...

Drawdown Indicators

IHEGERMDifference

Max Drawdown

Largest peak-to-trough decline

-38.20%

0.00%

-38.20%

Max Drawdown (1Y)

Largest decline over 1 year

-8.47%

0.00%

-8.47%

Max Drawdown (3Y)

Largest decline over 3 years

-15.92%

—

—

Max Drawdown (5Y)

Largest decline over 5 years

-16.03%

—

—

Max Drawdown (10Y)

Largest decline over 10 years

-29.59%

—

—

Current Drawdown

Current decline from peak

0.00%

0.00%

0.00%

Average Drawdown

Average peak-to-trough decline

-7.90%

0.00%

-7.90%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.75%

0.00%

+2.75%

Volatility

IHE vs. GERM - Volatility Comparison

iShares U.S. Pharmaceuticals ETF (IHE) has a higher volatility of 5.26% compared to Amplify Treatments, Testing and Advancements ETF (GERM) at 0.00%. This indicates that IHE's price experiences larger fluctuations and is considered to be riskier than GERM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading charts...

Volatility by Period

IHEGERMDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.26%

0.00%

+5.26%

Volatility (6M)

Calculated over the trailing 6-month period

12.69%

0.00%

+12.69%

Volatility (1Y)

Calculated over the trailing 1-year period

17.23%

0.00%

+17.23%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

16.29%

0.00%

+16.29%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

18.04%

0.00%

+18.04%

IHE vs. GERM - Expense Ratio Comparison

IHE has a 0.42% expense ratio, which is lower than GERM's 0.68% expense ratio.

Dividends

IHE vs. GERM - Dividend Comparison

IHE's dividend yield for the trailing twelve months is around 1.53%, while GERM has not paid dividends to shareholders.

PositionTTM20252024202320222021202020192018201720162015
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
IHE
iShares U.S. Pharmaceuticals ETF		1.53%1.76%1.73%1.39%2.01%1.49%1.19%1.40%1.25%1.36%0.92%1.93%

Frequently Asked Questions

IHE has higher volatility (5.26%) compared to GERM (0.00%). In terms of maximum drawdown, IHE dropped -38.20% vs GERM's 0.00%.

On 1-year performance, IHE leads with 48.10% vs 0.00% for GERM. On fees, IHE is cheaper at 0.42% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, IHE has performed better with a 48.10% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IHE is cheaper with a 0.42% expense ratio, compared with 0.68% for GERM.

IHE has the higher dividend yield at 1.53%, compared with 0.00% for GERM.

IHE tracks Dow Jones U.S. Select Pharmaceuticals Index, while GERM tracks Prime Treatments, Testing and Advancements Index. They also come from different issuers: iShares and Amplify. Their fees differ too: 0.42% for IHE and 0.68% for GERM.

Portfolio Optimizer

Find the right allocation for IHE and GERM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer